Detalhe da pesquisa
1.
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
Drug Metab Dispos
; 50(5): 576-590, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35153195
2.
Current practices for QSP model assessment: an IQ consortium survey.
J Pharmacokinet Pharmacodyn
; 2022 Aug 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35953664
3.
A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.
J Pharmacokinet Pharmacodyn
; 47(2): 163-182, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32162138
4.
A Computational Modeling and Simulation Approach to Investigate Mechanisms of Subcellular cAMP Compartmentation.
PLoS Comput Biol
; 12(7): e1005005, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27409243
5.
Using Markov state models to develop a mechanistic understanding of protein kinase A regulatory subunit RIα activation in response to cAMP binding.
J Biol Chem
; 289(43): 30040-51, 2014 Oct 24.
Artigo
Inglês
| MEDLINE | ID: mdl-25202018
6.
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.
J Med Chem
; 2024 Apr 30.
Artigo
Inglês
| MEDLINE | ID: mdl-38687966
7.
Nanoparticles for improved local retention after intra-articular injection into the knee joint.
Pharm Res
; 30(1): 257-68, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-22996566
8.
A whole-body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studies.
CPT Pharmacometrics Syst Pharmacol
; 10(7): 671-683, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33793091
9.
Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.
J Med Chem
; 64(13): 9056-9077, 2021 07 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34110834
10.
Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.
Cancer Cell
; 39(10): 1404-1421.e11, 2021 10 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34520734
11.
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.
Nat Commun
; 12(1): 6055, 2021 10 18.
Artigo
Inglês
| MEDLINE | ID: mdl-34663813
12.
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.
Science
; 374(6575): 1586-1593, 2021 Dec 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34726479
13.
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19.
bioRxiv
; 2021 Feb 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32935104
14.
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
AAPS J
; 22(6): 143, 2020 11 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33156437
15.
Bridging scales through multiscale modeling: a case study on protein kinase A.
Front Physiol
; 6: 250, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26441670